Jump To


  • Generic Name: insulin (human recombinant)
  • Brand Name: Humulin 70-30
Last updated on MDtodate: 10/6/2022


The following adverse reactions are discussed elsewhere in the labeling:

  • Hypoglycemia
  • Hypokalemia

The following additional adverse reactions have been identified during post-approval use of HUMULIN 70/30. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or to establish a causal relationship to drug exposure.

Allergic Reactions

Some patients taking HUMULIN 70/30 have experienced erythema, local edema, and pruritus at the site of injection. These conditions were usually self-limiting. Severe cases of generalized allergy (anaphylaxis) have been reported.

Peripheral Edema

Some patients taking HUMULIN 70/30 have experienced sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy.


Administration of insulin subcutaneously, including HUMULIN 70/30, has resulted in lipoatrophy (depression in the skin) or lipohypertrophy (enlargement or thickening of tissue) in some patients.

Weight gain

Weight gain has occurred with some insulin therapies including HUMULIN 70/30 and has been attributed to the anabolic effects of insulin and the decrease in glycosuria.


Development of antibodies that react with human insulin have been observed with all insulin, including HUMULIN 70/30.



Read Next Article

PHP Code Snippets Powered By : XYZScripts.com